Night vision often fades first, followed by a narrowing of peripheral vision. In retinitis pigmentosa, this progressive loss can eventually lead to blindness. An experimental treatment has now helped ...
What I think about now, while trying for my third child, having started fertility treatment at 32Good evening!Lately, I've ...
Slimmers in the US are seeking damages after the injections allegedly caused a condition that cuts off blood supply to the ...
GLP-1 receptor agonists did not significantly affect anti-VEGF treatment frequency in patients with diabetic macular edema ...
New Zealand's Northern B ethics committee rejected OliX's Phase 2a trial application for macular degeneration drug OLX10212, ...
Roche advances vamikibart toward potential US approval after phase III trials show sustained vision improvements, reduced ...
One year on from a mixed phase 3 readout, Roche has shared updated data from eye disease trials that could support FDA ...
RESTORE-3 study demonstrates a 60.4% proptosis response rate versus 23.5% with placebo at Week 24, highlighting the potential ...
Roche’s vamikibart shows 1-year vision gains in Phase 3 uveitic macular edema trials, offering a non-steroid alternative; see ...
Merck ( MRK) said its experimental eye drug remigromig improved vision in patients with a diabetes-related eye disease, ...
A new study shows that the dual EZH1/2 inhibitor valemetostat counteracts HTLV-1-induced epigenetic changes in retinal cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results